- Home
- NERV vs CLRB Comparison
NERV vs CLRB Comparison
Compare NERV & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- CLRB
- Stock Information
- Founded
- NERV 2007
- CLRB 2002
- Country
- NERV United States
- CLRB United States
- Employees
- NERV N/A
- CLRB N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- CLRB Health Care
- Exchange
- NERV Nasdaq
- CLRB Nasdaq
- Market Cap
- NERV 15.5M
- CLRB 15.3M
- IPO Year
- NERV 2014
- CLRB N/A
- Fundamental
- Price
- NERV $1.82
- CLRB $0.31
- Analyst Decision
- NERV Hold
- CLRB Buy
- Analyst Count
- NERV 1
- CLRB 2
- Target Price
- NERV $5.00
- CLRB $28.00
- AVG Volume (30 Days)
- NERV 77.1K
- CLRB 1.4M
- Earning Date
- NERV 03-04-2025
- CLRB 03-26-2025
- Dividend Yield
- NERV N/A
- CLRB N/A
- EPS Growth
- NERV N/A
- CLRB N/A
- EPS
- NERV N/A
- CLRB N/A
- Revenue
- NERV N/A
- CLRB N/A
- Revenue This Year
- NERV N/A
- CLRB N/A
- Revenue Next Year
- NERV N/A
- CLRB N/A
- P/E Ratio
- NERV N/A
- CLRB N/A
- Revenue Growth
- NERV N/A
- CLRB N/A
- 52 Week Low
- NERV $1.77
- CLRB $0.22
- 52 Week High
- NERV $7.53
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- NERV 34.70
- CLRB 46.10
- Support Level
- NERV $1.77
- CLRB $0.26
- Resistance Level
- NERV $2.05
- CLRB $0.35
- Average True Range (ATR)
- NERV 0.16
- CLRB 0.03
- MACD
- NERV -0.04
- CLRB 0.02
- Stochastic Oscillator
- NERV 6.41
- CLRB 61.40
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.